Research Desk Line-up: Biostar Pharma Post Earnings Coverage

LONDON, UK / ACCESSWIRE / June 16, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for Johnson & Johnson (NYSE: JNJ). The Company announced on June 14, 2017, that its experimental flu drug significantly reduced the presence of the virus in patients with a type of influenza, in a mid-stage study. The Company aims to treat influenza patients, who have developed resistance to existing antiviral drugs through its pioneering, antiviral drug, pimodivir. For immediate access to our complimentary reports, including today's coverage, register for free now at:

http://protraderdaily.com/register/

Discover more of our free reports coverage from other companies within the Drug Manufacturers - Major industry. Pro-TD has currently selected Biostar Pharmaceuticals, Inc. (NASDAQ: BSPM) for due-diligence and potential coverage as the Company announced on May 19, 2017, its financial results for Q1 which ended on March 31, 2017. Tune in to our site to register for a free membership, and be among the early birds that get our report on Biostar Pharma when we publish it.

At Pro-TD, we make it our mission to bring you news that matter about the stock you follow. Today, our research desk covers a blog story on JNJ; also brushing on BSPM. Go directly to your stock of interest and access today's free coverage at:

http://protraderdaily.com/optin/?symbol=JNJ

http://protraderdaily.com/optin/?symbol=BSPM

The Announcement

According to the announcement, more than 1 billion people suffer from influenza each year, across the world. These 1 billion influenza cases are followed by five million cases of severe illness and about 500 thousand deaths. Influenza viruses are known to evolve from one season to the next, and at times, change the same course in the same season. Hence, as the virus replicates, the genetic buildup of the being may change, resulting in the virus being resistant to the treatment used. Currently, there are three antiviral drugs recommended by the US Centers for Disease Control & Prevention and they include: oseltamivir (also known as Tamiflu), zanamivir, and peramivir.

Pimodivir

Pimodivir was granted the US Food and Drug Administration's "fast-track" status in March 2017, owing to its potential to address medication for patients who develop the influenza A and are hospitalized or at high risk of related complications.

The Company tested pimodivir as a mono-therapy or in combination with a widely used flu drug, oseltamivir, for the treatment of uncomplicated seasonal influenza. Pimodivir targets another part of the viral replication process when compared against oseltamivir. If successful, the Pimodivir will enable the treatment of Type A influenza patients who have developed resistance to existing treatments. According to the trial data, treatment with pimodivir resulted in a statistically significant reduction in viral load present in patients over seven days from the start of dosing, when compared to Placebo. Administering pimodivir with oseltamivir resulted in significantly lower viral load compared to those who received pimodivir, individually, according to the Company.

Johnson & Johnson purchased the worldwide rights to pimodivir from Vertex Pharmaceuticals, Inc. in 2014, where its development is being funded partially by the US Department of Health and Human Services. Johnson & Johnson expects to begin a late-stage trial for pimodivir in the second half of 2017.

Johnson & Johnson Growth Prospects

On May 17, 2017, the Company showcased its pipeline of Transformational Medicines of more than 10 new products which are expected to launch or file for regulatory approval by 2021. Johnson & Johnson currently has a workforce of 130,800 employees at more than 250 Operating Companies and works closely with leading pharmaceutical conglomerates to deliver leading solutions. The Company additionally holds about 50-plus line extensions of existing and new medicines to provide better treatment and immunity for a broader patient population. The Company announced that it plans to file multiple products for regulatory approvals midst 2017 and 2021, which includes pimodivir (JNJ-3872) for influenza A, and lumicitabine (JNJ-1575) for respiratory syncytial virus (RSV) infection.

Last Close Stock Review

On Thursday, June 15, 2017, the stock closed the trading session at $133.04, slightly up 0.20% from its previous closing price of $132.77. A total volume of 5.26 million shares have exchanged hands. Johnson & Johnson's stock price rallied 3.57% in the last three months, 14.80% in the past six months, and 14.29% in the previous twelve months. Furthermore, since the start of the year, shares of the Company have surged 15.48%. The stock is trading at a PE ratio of 22.36 and has a dividend yield of 2.53%. At Thursday's closing price, the stock's net capitalization stands at $358.94 billion.

Pro-Trader Daily:

Pro-Trader Daily (Pro-TD) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. PRO-TD has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

PRO-TD has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst, for further information on analyst credentials, please email contact@protraderdaily.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by PRO-TD. PRO-TD is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

PRO-TD, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. PRO-TD, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, PRO-TD, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither PRO-TD nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://protraderdaily.com/disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: contact@protraderdaily.com

Phone number: (917) 341.4653

Office Address: Mainzer Landstrasse 50 Frankfurt am Main, Germany 60325

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Pro-Trader Daily